Skip to main content



14-09-2020 | Rheumatology | News | Article

Cardiovascular damage apparent in early RA

Individuals with treatment-naïve early rheumatoid arthritis show evidence of cardiovascular disease that improves following initiation of DMARD therapy, UK research shows.

08-09-2020 | Diabetes | News | Article

Meta-analysis supports mortality reduction with SGLT2 inhibition in HF

A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.

02-09-2020 | Diabetes | News | Article

Age, cardiovascular disease impact amputation risk with canagliflozin

Older patients and those with cardiovascular disease are most likely to have an increased risk for lower limb amputation when newly prescribed canagliflozin, relative to a GLP-1 receptor agonist, research shows.

02-09-2020 | Rheumatology | News | Article

Abatacept, TNF inhibitors linked to reduced CVD risk in RA

A real-world comparison of biologic, targeted synthetic, and conventional DMARDs indicates that TNF inhibitors and abatacept are associated with a reduction in CVD risk in patients with rheumatoid arthritis.

01-09-2020 | Diabetes | News | Article

EMPEROR-Reduced boosts case for SGLT2 inhibition in HF irrespective of diabetes

The EMPEROR-Reduced investigators have revealed that empagliflozin provides significant protection against cardiovascular death and heart failure in patients with heart failure and reduced ejection fraction, with or without diabetes.

21-08-2020 | Diabetes | News | Article

Fasting glucose variability in young adulthood linked to CAC progression in middle age

A prospective study has revealed that greater fasting glucose variability during young adulthood is independently associated with increased risk for coronary artery calcification progression in middle age.

14-08-2020 | Diabetes | News | Article

Dapagliflozin not linked to adverse limb events in DECLARE-TIMI 58

Dapagliflozin reduces the risk for cardiovascular events in people with type 2 diabetes, including those with peripheral artery disease, without increasing the risk for adverse limb events, show DECLARE-TIMI 58 data.

17-07-2020 | Diabetes | News | Article

Updated meta-analysis confirms prediabetes link with mortality, CVD risk

Prediabetes is associated with an elevated risk for all-cause mortality and cardiovascular events, both in the general population and in patients with atherosclerotic cardiovascular disease, shows an updated meta-analysis published in The BMJ.

16-06-2020 | Diabetes | News | Article

VERTIS-CV: Similar MACE risk with ertugliflozin vs placebo in type 2 diabetes

Patients with type 2 diabetes and established atherosclerotic disease who are treated with the SGLT2 inhibitor ertugliflozin have a similar risk for major adverse cardiovascular events to those given placebo, shows the VERTIS-CV trial.

13-06-2020 | Diabetes | News | Article

Icosapent ethyl lowers cardiovascular risk in people with diabetes

Icosapent ethyl reduces the risk for first and total cardiovascular events in statin-treated patients with diabetes, suggests a subgroup analysis of the REDUCE-IT trial.

28-04-2020 | Diabetes | News | Article

Updated analysis shows cardiovascular benefits of type 2 diabetes therapies

Glucose-lowering drugs or strategies reduce the risk for major adverse cardiovascular events and death in people with or at risk for type 2 diabetes, but their impact on heart failure may depend on weight loss, shows an updated systematic review and meta-analysis.

02-04-2020 | Diabetes | News | Article

Add-on rivaroxaban has cardiovascular benefits irrespective of diabetes status

The addition of rivaroxaban to aspirin results in a similar relative reduction in the risk for cardiovascular events among patients with stable atherosclerosis and a history of atherosclerotic disease regardless of whether or not they have diabetes, suggests a subgroup analysis of the COMPASS trial.

31-03-2020 | Diabetes | News | Article

Cardioprotective benefits of dapagliflozin extend beyond people with diabetes

Treatment with dapagliflozin is associated with a significant reduction in the risk for heart failure worsening or cardiovascular death in people with heart failure and reduced ejection fraction regardless of whether or not they have diabetes, shows an exploratory analysis of DAPA-HF trial data.

26-02-2020 | Diabetes | News | Article

Urgent action needed to improve dysglycemia screening in patients with heart disease

More than half of people with coronary artery disease have impaired glucose tolerance, yet many are unaware of this or are undertreated despite knowledge of their condition, results of the EUROASPIRE V survey show.

04-02-2020 | Rheumatology | News | Article

Multidisciplinary approach needed for rheumatology patients with coronary artery disease

An analysis of percutaneous coronary intervention outcomes among people with rheumatic diseases suggests that those with systemic sclerosis have an elevated risk for multiple in-hospital complications, while patients with systemic lupus erythematosus have an increased bleeding risk.

30-01-2020 | Oncology | News | Article

ESMO cardiovascular toxicity care recommendations released

Read more on these guidelines here

05-12-2019 | Diabetes | News | Article

Children of mothers with diabetes may have elevated CVD risk

Children born to mothers with diabetes have a higher risk for early-onset, non-congenital cardiovascular disease in childhood and early adulthood than those born to mothers without diabetes, suggest findings from a large observational study.

04-09-2019 | Diabetes | News | Article

Real-world data verify cardioprotective benefits of SGLT2 inhibitors

Real-world data published in The BMJ confirm the cardioprotective benefits of SGLT2 inhibitor use, relative to DPP-4 inhibitor use, in people with type 2 diabetes.

02-09-2019 | Oncology | Main feed | Article

Elevated cardiovascular risk seen in survivors of most common cancers

Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.

01-09-2019 | Diabetes | News | Article

THEMIS: No overall benefit of ticagrelor in people with diabetes, coronary artery disease

Findings from the THEMIS trial suggest that the addition of ticagrelor to aspirin treatment reduces the incidence of ischemic cardiovascular events among people with type 2 diabetes and stable coronary artery disease, but at the cost of an increased risk for major bleeding, resulting in an unfavorable risk:benefit ratio.

Image Credits